Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?

Chouillard, Élie; Greco, Vincenzo J.; Tsiminikakis, N.

doi:10.1007/s10151-013-1063-2

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believe that this issue can be clarified with future studies involving larger and homogeneous cohorts. Reportedly, the peritoneum is another common site of CRC metastasis ( 28 ), and the degree of peritoneal metastasis determines the choice of treatment ( 23 , 29 ). The detection rate of peritoneal metastasis using [ 18 F]F-FDG PET/CT is not high, primarily because of intestinal inflammatory uptake, small lesions and other factors, including rare pathological types.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of [68Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET/CT

Lin

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

PurposeThis study aimed to compare the diagnostic performance of [68Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in primary and metastatic colorectal cancer (CRC) lesions.MethodsThis single-center preliminary clinical study (NCT04750772) was conducted at the Peking University Cancer Hospital & Institute and included 61 participants with CRC who underwent sequential evaluation through PET/CT with [18F]F-FDG and [68Ga]Ga-FAPI-04. Their PET/CT images were analysed to quantify the uptake of the two tracers in the form of maximum standardised uptake (SUVmax) values and target-to-background ratio (TBR), which were then compared using Wilcoxon’s signed-rank test. The final changes in the tumour–node–metastasis (TNM) stage of all participants were recorded.ResultsOf all the participants, 21 were treatment naïve and 40 had been previously treated. In primary CRC lesions, the average TBRs of [68Ga]Ga-FAPI-04 and [18F]F-FDG were 13.3 ± 8.9 and 8.2 ± 6.5, respectively. The SUVmax of [68Ga]Ga-FAPI-04 in signet-ring/mucinous carcinomas (11.4 ± 4.9) was higher than that of [18F]F-FDG (7.9 ± 3.6) (P = 0.03). Both median SUVmax in peritoneal metastases and TBR in liver metastases of [68Ga]Ga-FAPI-04 were higher than those of [18F]F-FDG (5.2 vs. 3.8, P < 0.001; 3.7 vs. 1.9, P < 0.001, respectively). Compared with [18F]F-FDG PET/CT, clinical TNM staging based on [68Ga]Ga-FAPI-04 PET/CT led to upstaging and downstaging in 10 (16.4%) and 5 participants (8.2%), respectively. Therefore, the treatment options were changed in 13 participants (21.3%), including 9 with additional chemo/radiotherapy and/or surgery and others with avoidance or narrowed scope of surgery.Conclusion[68Ga]Ga-FAPI-04 showed potential as a novel PET/CT tracer to detect lymph nodes and distant metastases, which improved CRC staging, thus prompting the optimisation or adjustment of treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic value of [68Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET/CT

Lin

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Peritoneum is another common site of CRC metastasis [29] and the degree of peritoneal metastasis also determines the choice of treatment [24,30,31]. The detection rate of peritoneal metastasis using 18 F-FDG PET/CT is not high, primarily due to intestinal in ammatory uptake, small lesions, and other factors including rare pathological types.…”

Section: Discussionmentioning

confidence: 99%

68Ga-FAPI improves tumor staging in patients with colorectal cancer: comparing to 18F-FDG PET/CT

Lin

Wang

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose Gallium-68 (68Ga)-labeled fibroblast-activation protein inhibitor (FAPI) is a novel tracer that binds fibroblast-activation protein (FAP), which is overexpressed in colorectal cancers with a prominent stroma including cancer-associated fibroblasts (CAFs). The present study aimed to compare the diagnostic performance of 68Ga-FAPI positron emission tomography (PET)/computed tomography (CT) with that of fluorine-18 (18F)-fluorodeoxyglucose (FDG) PET/CT in primary and metastatic colorectal cancer lesions. Methods This prospective study included the image analyses of 37 patients with colorectal cancer who were sequentially evaluated using PET/CT with 18F-FDG and 68Ga-FAPI. Tracer uptakes were compared using Wilcoxon’s signed-rank test. Results The cohort comprised 37 patients, including 18 treatment-naïve patients and 19 post-treatment patients. In primary colorectal cancer lesions, the average 68Ga-FAPI and 18F-FDG maximum standardized uptake values (SUVmax) were 12.5 ± 4.8 and 13.2 ± 5.7 (P = 0.38), respectively, in the treatment-naïve group and 6.0 ± 4.3 and 7.9 ± 7.2, respectively, in the neoadjuvant chemotherapy group (P = 0.09); the detection rate was 100% with both tracers (18/18). The SUVmax value of 68Ga-FAPI in signet-ring/mucinous carcinomas (12.3 ± 5.2) was higher than that of 18F-FDG (8.3 ± 4.0) (P = 0.03). In addition, the average 68Ga-FAPI uptake was lower than that of 18F-FDG in poorly differentiated carcinomas (12.7 ± 3.7 vs. 18.1 ± 4.1, P = 0.04). Compared with 18F-FDG PET/CT, clinical TNM staging based on 68Ga-FAPI PET/CT led to upstaging in 6 patients (16.2%) and downstaging in 3 patients (8.1%). In peritoneal and liver metastases, both the SUVmax and the target/background ratio were higher with 68Ga-FAPI compared to 18F-FDG (3.7 vs. 2.6, P = 0.02, and 6.5 vs. 0.89, P = 0.01, respectively). Conclusion As a novel PET/CT tracer, 68Ga-FAPI showed its advantage in the detection of lymph nodes, and distant metastases, which improved staging of CRC.

show abstract

Preventive intraperitoneal hyperthermic perfusion chemotherapy for patients with T4 stage colon adenocarcinoma

et al. 2020

Tech Coloproctol

View full text Add to dashboard Cite

Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?

Cited by 3 publications

References 18 publications

Diagnostic value of [68Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET/CT

Diagnostic value of [68Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET/CT

68Ga-FAPI improves tumor staging in patients with colorectal cancer: comparing to 18F-FDG PET/CT

Preventive intraperitoneal hyperthermic perfusion chemotherapy for patients with T4 stage colon adenocarcinoma

Contact Info

Product

Resources

About